Basilea Pharmaceutica is a Switzerland-based biopharmaceutical company, established in 2000 as a spin-out from Roche with the divestment of its anti-infective portfolio. It is listed on the SIX Swiss Stock Exchange and recently announced plans to focus strategically on anti-infectives. Revenue growth will continue to be driven from its two marketed anti-infectives, Cresemba (antifungal, for invasive mould infections) and Zevtera (antibiotic, for hospital infections). Currently, Cresemba is commercialised globally through partners such as Pfizer and Astellas. Basilea also announced plans to monetise its oncology assets (derazantinib, a pan-FGFR kinase inhibitor and lisavanbulin, a potential novel checkpoint inhibitor), which will free up resources and provide the company with incremental (financial) flexibility to fund its anti-infective strategy.
In this video, CEO David Veitch discusses the company’s anti-infective strategy.